{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+Head&page=85",
    "query": {
      "condition": "Cancer of Head",
      "page": 85
    },
    "page_size": 10
  },
  "pagination": {
    "page": 85,
    "page_size": 10,
    "total_count": 3019,
    "total_pages": 302,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+Head&page=86&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+Head&page=84&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T01:11:25.283Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05119296",
      "title": "Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Saad A Khan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2022-02-15",
      "completion_date": "2027-07",
      "has_results": true,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-11-21T01:11:25.283Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05119296"
    },
    {
      "nct_id": "NCT02186938",
      "title": "A Prospective Study Evaluating the Use of Intraoperative Stroke Volume Variation Via the FloTrac Device to Guide Fluid and Vasopressor Management in Head and Neck Free Flaps",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Patients Requiring a Free Flap Surgery"
      ],
      "interventions": [
        {
          "name": "FloTrac",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2012-12",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2018-09-20",
      "last_synced_at": "2026-11-21T01:11:25.283Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02186938"
    },
    {
      "nct_id": "NCT01183559",
      "title": "A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer of the Esophagus",
        "Adenocarcinoma of the Gastroesophageal Junction",
        "Cancer of the Stomach"
      ],
      "interventions": [
        {
          "name": "Vandetanib",
          "type": "DRUG"
        },
        {
          "name": "5 Fluorouracil (FU)",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "External Beam Radiation Therapy (RT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2008-08-07",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-11-21T01:11:25.283Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01183559"
    },
    {
      "nct_id": "NCT03233724",
      "title": "Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Lung Cancer",
        "Non-Small Cell Lung Cancer",
        "Carcinoma, Esophageal",
        "Malignant Pleural Mesotheliomas"
      ],
      "interventions": [
        {
          "name": "Decitabine (DAC)",
          "type": "DRUG"
        },
        {
          "name": "Tetrahydrouridine (THU)",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 9,
      "start_date": "2018-04-11",
      "completion_date": "2021-10-26",
      "has_results": true,
      "last_update_posted_date": "2023-05-31",
      "last_synced_at": "2026-11-21T01:11:25.283Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03233724"
    },
    {
      "nct_id": "NCT02072148",
      "title": "The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Human Papilloma Virus",
        "Oropharyngeal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "PET/CT",
          "type": "PROCEDURE"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Concurrent Chemoradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2014-03",
      "completion_date": "2022-05-12",
      "has_results": true,
      "last_update_posted_date": "2024-05-06",
      "last_synced_at": "2026-11-21T01:11:25.283Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02072148"
    },
    {
      "nct_id": "NCT03049358",
      "title": "Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With Paranasal Sinus or Nasopharyngeal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stage 0 Nasopharyngeal Carcinoma",
        "Stage 0 Paranasal Sinus Cancer",
        "Stage I Nasopharyngeal Carcinoma",
        "Stage I Paranasal Sinus Cancer",
        "Stage II Nasopharyngeal Carcinoma",
        "Stage II Paranasal Sinus Cancer",
        "Stage IIA Nasopharyngeal Carcinoma",
        "Stage IIB Nasopharyngeal Carcinoma",
        "Stage III Nasopharyngeal Carcinoma",
        "Stage III Paranasal Sinus Cancer",
        "Stage IV Nasopharyngeal Carcinoma",
        "Stage IV Paranasal Sinus Cancer",
        "Stage IVA Nasopharyngeal Carcinoma",
        "Stage IVA Paranasal Sinus Cancer",
        "Stage IVB Nasopharyngeal Carcinoma",
        "Stage IVB Paranasal Sinus Cancer",
        "Stage IVC Nasopharyngeal Carcinoma",
        "Stage IVC Paranasal Sinus Cancer"
      ],
      "interventions": [
        {
          "name": "Physiologic Testing",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Sham Intervention",
          "type": "PROCEDURE"
        },
        {
          "name": "Therapeutic Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "rose essential oil",
          "type": "OTHER"
        },
        {
          "name": "lemon essential oil",
          "type": "OTHER"
        },
        {
          "name": "clove essential oil",
          "type": "OTHER"
        },
        {
          "name": "eucalyptus essential oil",
          "type": "OTHER"
        },
        {
          "name": "canola oil placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2016-12",
      "completion_date": "2018-10",
      "has_results": false,
      "last_update_posted_date": "2019-02-05",
      "last_synced_at": "2026-11-21T01:11:25.283Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03049358"
    },
    {
      "nct_id": "NCT00098813",
      "title": "Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Thyroid Cancer",
        "Stage IV Follicular Thyroid Cancer",
        "Stage IV Papillary Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "romidepsin",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "positron emission tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2004-10",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2014-05-28",
      "last_synced_at": "2026-11-21T01:11:25.283Z",
      "location_count": 1,
      "location_summary": "Commack, New York",
      "locations": [
        {
          "city": "Commack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00098813"
    },
    {
      "nct_id": "NCT03543813",
      "title": "PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Head and Neck Cancer",
        "Non Small Cell Lung Cancer",
        "Diffuse Large B Cell Lymphoma",
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "CX-2029",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytomX Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 133,
      "start_date": "2018-06-15",
      "completion_date": "2023-06-01",
      "has_results": false,
      "last_update_posted_date": "2024-01-23",
      "last_synced_at": "2026-11-21T01:11:25.283Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Encinitas, California • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03543813"
    },
    {
      "nct_id": "NCT01663259",
      "title": "Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Oropharynx",
        "HPV"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2011-01",
      "completion_date": "2019-09",
      "has_results": true,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-11-21T01:11:25.283Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01663259"
    },
    {
      "nct_id": "NCT01512589",
      "title": "Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "Proton Beam Therapy (PBT)",
          "type": "RADIATION"
        },
        {
          "name": "Intensity Modulated Radiation Therapy (IMRT)",
          "type": "RADIATION"
        },
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 147,
      "start_date": "2012-04-30",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-21T01:11:25.283Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01512589"
    }
  ]
}